Use of erythropoietin-derived peptide through effect on cell damage prevention thereof

Abstract

A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage.

1 . A peptide described by any one amino acid sequence selected from the group consisting of SEQ ID NOS: 1 or 9. 
     
     
         2 . The peptide of  claim 1 , wherein the peptide is derived from an erythropoietin protein sequence. 
     
     
         3 . The peptide of  claim 1 , wherein the peptide binds to an erythropoietin receptor. 
     
     
         4 . The peptide of  claim 1 , wherein the peptide forms an alpha-helical structure. 
     
     
         5 . The peptide of  claim 1 , wherein the peptide exhibits cell protective activity. 
     
     
         6 . The peptide of  claim 1 , wherein the peptide has no side effect of cell proliferation. 
     
     
         7 . A pharmaceutical composition for preventing or treating a neurodegenerative disease, the pharmaceutical composition comprising,
 as an active ingredient, the peptide of  claim 1 , one or more polynucleotides encoding the peptide, a vector comprising the polynucleotide, or a host cell comprising the vector.   
     
     
         8 . The pharmaceutical composition for preventing or treating a neurodegenerative disease of  claim 7 , wherein the neurodegenerative disease is any one selected from the group consisting of stroke, paralysis, myocardial infarction, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, Pick's disease, and Creutzfeldt-Jakob disease. 
     
     
         9 . The pharmaceutical composition for preventing or treating a neurodegenerative disease of  claim 7 , wherein the host cell is an HEK-293E cell, a Chinese hamster ovary (CHO) cell, a baby hamster kidney (BHK) cell, an NIH-3T3 cell, an HEK-293T cell, or a COS-7 cell. 
     
     
         10 . The pharmaceutical composition for preventing or treating a neurodegenerative disease of  claim 7 , wherein the vector is a linear DNA vector, a plasmid DNA vector, or a recombinant viral vector. 
     
     
         11 . The pharmaceutical composition for preventing or treating a neurodegenerative disease of  claim 10 , wherein the recombinant virus is any one selected from the group consisting of retroviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, and lentiviruses. 
     
     
         12 . A method of preventing or treating a neurodegenerative disease, the method comprising:
 administering a composition comprising, as an active ingredient, the peptide of  claim 1 , one or more polynucleotides encoding the peptide, a vector comprising the polynucleotide, or a host cell comprising the vector.   
     
     
         13 . Use of a composition comprising,
 as an active ingredient, the peptide of  claim 1 , one or more polynucleotides encoding the peptide, a vector comprising the polynucleotide, or a host cell comprising the vector in the preparation of a prophylactic or therapeutic agent for a neurodegenerative disease.